Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008R. Phillip Dellinger, Jean Carlet, Julian Bion et al.|Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)|2008Cited by 3.9k
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)Steven M. Opal, Gordon R. Bernard, Gary Garber et al.|Clinical Infectious Diseases|2003Cited by 192
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*Steven M. Opal, John P. Pribble, Pierre‐François Laterre et al.|Critical Care Medicine|2004Cited by 145